{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"39.1","upperLimit":"53.7","value":"46.3"}]}],"title":"Week 96 response"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"38.6","upperLimit":"53.2","value":"45.8"}]}],"title":"Week 144 response"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"36.0","upperLimit":"50.5","value":"43.2"}]}],"title":"Week 192 response"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"33.0","upperLimit":"47.3","value":"40.0"}]}],"title":"Week 264 response"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"31.0","upperLimit":"45.2","value":"37.9"}]}],"title":"Week 312 (Year 6) response"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"29.5","upperLimit":"43.6","value":"36.3"}]}],"title":"Week 360 (Year 7) response"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"28.5","upperLimit":"42.5","value":"35.3"}]}],"title":"Week 408 (year 8) response"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"27.0","upperLimit":"40.9","value":"33.7"}]}],"title":"Week 468 (year 9) response"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19.3","upperLimit":"32.1","value":"25.3"}]}],"title":"Week 528 (year 10) response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"190"}],"units":"Participants"}],"description":"This secondary outcome measure was the percentage of participants in molecular response 4.5 (MR4.5) assessed at multiple timepoints after initiation of the treatment-free remission (TFR) phase. Participants who required reinitiation of treatment at any time prior to the respective assessment were considered non-responders. MR4.5 corresponds to a BCR-ABL transcript level ≤0.0032% on the International Scale (IS).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who completed the nilotinib treatment consolidation (NTCS) phase and maintained major molecular response entered the treatment-free remission (TFR) phase. During the TFR phase, nilotinib treatment was discontinued and participants were monitored regularly for molecular response.","id":"OG000","title":"TFR Phase"}],"paramType":"NUMBER","populationDescription":"The full analysis set (FAS) included all participants who completed 52 weeks of nilotinib treatment in the NTCS phase and subsequently entered the TFR phase","reportingStatus":"POSTED","timeFrame":"Weeks 96, 144, 192, and 264, and End of Years 6, 7, 8, 9, and 10","title":"Percentage of Participants in Molecular Response 4.5 (MR4.5) at Multiple Time Points After Start of the Treatment-Free Remission (TFR) Phase","type":"SECONDARY","unitOfMeasure":"percentage of participants"}